Improved Gastrointestinal Involvement in Systemic Sclerosis after Immunoglobulin Treatment.
10.3904/kjm.2017.92.2.213
- Author:
Kyoung Jin CHOI
1
;
Jeong Hwa HWANG
;
Hyun Sook KIM
;
Joon Seong LEE
Author Information
1. Department of Internal Medicine, Soonchunhyang University College of Medicine, Seoul, Korea. healthyra@schmc.ac.kr
- Publication Type:Case Report
- Keywords:
Systemic sclerosis;
Gastrointestinal involvement;
Immunoglobulin
- MeSH:
Autoimmune Diseases;
Cough;
Fibrosis;
Heart;
Humans;
Immunoglobulins*;
Kidney;
Lung;
Mortality;
Scleroderma, Diffuse;
Scleroderma, Systemic*
- From:Korean Journal of Medicine
2017;92(2):213-218
- CountryRepublic of Korea
- Language:Korean
-
Abstract:
Systemic sclerosis is an intractable clinical subset characterized by diffuse fibrosis, vasculopathy, and immune abnormalities. Diffuse cutaneous systemic sclerosis has a variety of symptoms depending on the internal organs involved, such as the lungs, heart, kidneys, and gastrointestinal system. Gastrointestinal involvement is frequent and one of the major cause of morbidity and mortality. There is no sustained, effective therapy for treating the active gastrointestinal involvement of systemic sclerosis. Although immunoglobulin is commonly used in the treatment of other autoimmune diseases, its effects in the treatment of the gastrointestinal involvement in systemic sclerosis are unclear. Here, we report a patient with a severe cough caused by uncontrolled gastrointestinal involvement in diffuse cutaneous systemic sclerosis treated with immunoglobulin.
